EGFR CART Cells for Patients With Metastatic Colorectal Cancer

Inclusion Criteria: * 1\. Patients must be 18 years to 70 years; * 2\. Clinical diagnosis of EGFR positive for patients with metastatic colorectal cancer; * 3\. Patients must have a KPS of \>80, expected survival \> 3 months; * 4\. Patients must have at least one measurable lesions; * 5\. Recently did not use glucocorticoid; * 6\. Patients must have evidence of adequate hepatic and renal function as evidenced by the following laboratory parameters: WBC ≥ 4.0×109/L, Hb ≥90 g/L, PLT ≥100×109/L）; AST ≤2.5ULN，ALT ≤ 2.5ULN; Cr≤ 3ULN; TBIL≤ 3ULN， * 7\. Patients must have a good heart function (LVEF\>50%) ; * 8\. Patients must be willing to practice birth control during and for three months following treatment.NOTE:female participants of reproductive potential must have a negative serum pregnancy test, and willing to practice birth control during and for three months following treatment； * 9\. Patients must be willing to sign an informed consent. Exclusion Criteria: * 1\. Patients with other cancer history; * 2\. Patients allergic to cetuximab; * 3\. Patients with severe bronchitis, bronchial asthma, or severs pneumonia; * 4\. Patients with uncontrolled active infections (bacteria, viruses or fungi infection) ; * 5\. Patients with acute and chronic GVHD (graft versus host disease) * 6\. Patients with severe autoimmune diseases; * 7\. Previously treatment with T cell inhibitors (cyclophosphamide, FK506); * 8\. Patients with active hepatitis B or hepatitis C infection, HIV infection, syphilis serology reaction positive; * 9\. Patients who are participating or participated any other clinical research in the past 1 months; * 10\. Pregnant and/or lactating women will be excluded;